Shares of Sientra Inc (NASDAQ:SIEN) have received a consensus recommendation of “Buy” from the nine analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $6.80.
A number of brokerages have recently commented on SIEN. SVB Leerink boosted their price target on Sientra from $5.30 to $6.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 11th. Maxim Group reiterated a “buy” rating and set a $8.00 price objective on shares of Sientra in a research note on Wednesday, August 12th. Canaccord Genuity reissued a “buy” rating and issued a $6.00 target price on shares of Sientra in a research note on Friday, August 14th. Finally, Zacks Investment Research downgraded Sientra from a “buy” rating to a “hold” rating in a report on Thursday, August 13th.
NASDAQ:SIEN opened at $3.69 on Thursday. The company has a debt-to-equity ratio of 2.87, a current ratio of 2.85 and a quick ratio of 1.95. The firm’s 50-day moving average price is $3.75 and its 200-day moving average price is $3.26. The company has a market capitalization of $185.65 million, a PE ratio of -1.75 and a beta of 1.52. Sientra has a 1-year low of $1.00 and a 1-year high of $9.71.
Sientra (NASDAQ:SIEN) last posted its quarterly earnings data on Monday, August 10th. The medical instruments supplier reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.23). The business had revenue of $12.45 million for the quarter, compared to the consensus estimate of $8.87 million. Sientra had a negative return on equity of 130.33% and a negative net margin of 140.76%. Equities analysts anticipate that Sientra will post -1.6 EPS for the current fiscal year.
Several hedge funds have recently bought and sold shares of the company. Cambridge Investment Research Advisors Inc. bought a new position in shares of Sientra during the first quarter valued at $30,000. Bank of Montreal Can bought a new stake in shares of Sientra in the second quarter worth approximately $39,000. Principal Financial Group Inc. purchased a new position in shares of Sientra during the second quarter valued at approximately $41,000. Wedbush Securities Inc. purchased a new stake in Sientra in the second quarter worth approximately $45,000. Finally, SG Americas Securities LLC bought a new stake in Sientra in the 1st quarter worth approximately $75,000. Hedge funds and other institutional investors own 76.86% of the company’s stock.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, OPUS, Dermaspan, Softspan, and BIOCORNEUM brand names.
Further Reading: What is a dead cat bounce?
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.